Blueprint Medicines - on May 22, After Exceeding Milestone From Sales of Ayvakit, Lenders Funded Tranche B Delayed Draw Term Loan of $150.0 Mln
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.